Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10710528 | 0.77 | — | — | |
| SCHEMBL18334352 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL8005036 | 0.74 | TDP1 (0.48) | SLC22A6TDP1SMN1; SMN2GABRR1LMNA | |
| SCHEMBL21433644 | 0.72 | — | — | |
| SCHEMBL27850812 | 0.72 | — | — | |
| SCHEMBL21433643 | 0.72 | — | — | |
| SCHEMBL22242591 | 0.71 | FOLH1 (0.46) | SLC22A6TDP1SMN1; SMN2GABRR1LMNA | |
| SCHEMBL21847998 | 0.70 | SLC22A6 (0.39) | SLC22A6TDP1SMN1; SMN2GABRR1LMNA | |
| SCHEMBL1032308 | 0.69 | — | — | |
| SCHEMBL22826570 | 0.69 | SLC22A6 (0.50) | SLC22A6TDP1SMN1; SMN2GABRR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662854-B2 | HIF hydroxylase inhibitors | ISIS INNOVATION LIMITED (GB) | 2010-02-16 | — | — | US | disclosed |
| US-7638295-B2 | Identifying agent which modulates 2-oxoglutarate dependent oxygenase; ankyrin substrate; hypoxia-inducible factor; thalassemia | ISIS INNOVATION LIMITED (GB) | 2009-12-29 | — | — | US | disclosed |
| EP-2065366-A2 | HIF hydroxylase inhibitors | ISIS Innovation Limited (GB) | 2009-06-03 | — | — | EP | disclosed |
| US-20080227848-A1 | Assays | ISIS INNOVATION LIMITED (GB) | 2008-09-18 | — | — | US | disclosed |
| CN-101199501-A | HIF hydroxylase inhibitors | ISIS INNOVATION (GB) | 2008-06-18 | — | — | CN | disclosed |
| CN-101199512-A | Hif hydroxylase inhibitors | ISIS INNOVATION (GB) | 2008-06-18 | — | — | CN | disclosed |
| CN-101199503-A | Hif hydroxylase inhibitors | ISIS INNOVATION (GB) | 2008-06-18 | — | — | CN | disclosed |
| CN-101199502-A | Hif hydroxylase inhibitors | ISIS INNOVATION (GB) | 2008-06-18 | — | — | CN | disclosed |
| CN-101199537-A | Hif hydroxylase inhibitors | ISIS INNOVATION (GB) | 2008-06-18 | — | — | CN | disclosed |
| US-20070066576-A1 | HIF hydroxylase inhibitors | ISIS INNOVATION LIMITED (GB) | 2007-03-22 | — | — | US | disclosed |
| EP-1733030-A2 | ASSAYS FOR IDENTIFYING MODULATORS OF THE HYDROXYLATION OF ANKYRIN REPEAT PROTEINS BY 2-OXOGLUTARATE DEPENDENT OXYGENASE AND METHODS OF USING THE SAME | ISIS INNOVATION LIMITED (GB) | 2006-12-20 | — | — | EP | disclosed |
| US-20050227948-A1 | Hif hydroxylase inhibitors | ISIS INNOVATION LIMITED (GB) | 2005-10-13 | — | — | US | disclosed |
| WO-2005093411-A2 | ASSAYS FOR IDENTIFYING MODULATORS OF THE HYDROXYLATION OF ANKYRIN REPEAT PROTEINS BY 2-OXOGLUTARATE DEPENDENT OXIGENASE AND METHODS OF USING THE SAME | ISIS INNOVATION LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| CN-1653040-A | HIF hydroxylase inhibitors | ISIS INNOVATION (GB) | 2005-08-10 | — | — | CN | disclosed |
| EP-1485347-A2 | HIF HYDROXYLASE INHIBITORS | ISIS INNOVATION LIMITED (GB) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003080566-A2 | HIF HYDROXYLASE INHIBITORS | ISIS INNOVATION LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227948-A1 | Hif hydroxylase inhibitors | HIF1AN, HIF1A, EGLN3 | SLC22A6 1155/4885TDP1 3910/4885SMN1; SMN2 4118/4885 |
| US-20070066576-A1 | HIF hydroxylase inhibitors | HIF1AN, HIF1A, EGLN3 | SLC22A6 1155/4885TDP1 3910/4885SMN1; SMN2 4118/4885 |
| US-20080227848-A1 | Assays | OGDH, HOGA1, OXGR1 | SLC22A6 2113/4885TDP1 1467/4885SMN1; SMN2 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.